Who makes VDMN-21 Patch Low Dose?

VDMN-21 Patch Low Dose is developed by Veradermics, Inc..

What development phase is VDMN-21 Patch Low Dose in?

VDMN-21 Patch Low Dose is in Phase 2.

Last reviewed 2026-04-19 · How we verify

VDMN-21 Patch Low Dose

Veradermics, Inc. · Phase 2 active Small molecule

VDMN-21 Patch Low Dose is a topical treatment developed by Veradermics, Inc. for common warts. It has completed Phase 2 trials demonstrating safety and efficacy. The patch is not yet FDA-approved but shows promise in dermatological applications.

At a glance

Generic name	VDMN-21 Patch Low Dose
Sponsor	Veradermics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VDMN-21 Patch Low Dose CI brief — competitive landscape report
VDMN-21 Patch Low Dose updates RSS · CI watch RSS
Veradermics, Inc. portfolio CI